TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1398851

Group type: EXPERIMENTAL
Intervention: Chloramphenicol succinate (CS) 50 mg/kg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chloramphenicol succinate (CS) 75 mg/kg/day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Chloramphenicol succinate (CS) 100 mg/kg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-typhoidal illnesses (control group)
Number of subjects: 40
Study: 2881900

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Propranolol plus Nifedipine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Atenolol plus Nifedipine
Number of subjects: 11
Study: 29571095

Group type: EXPERIMENTAL
Intervention: Behavioral interventions (specific types not detailed)
Number of subjects: 26495

Group type: COMPARATOR
Intervention: Control group (standard invitation letter)
Number of subjects: 26495
Study: 27033722

Group type: EXPERIMENTAL
Intervention: Culturally targeted intervention for diabetes management
Number of subjects: 248
Study: 23881909

Group type: EXPERIMENTAL
Intervention: Group problem-solving therapy (PST)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 58
Study: 24068395

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Radiochemotherapy with molecular anti-EGFR target therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Immunohistochemical staining for EGFR
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Ki67 index
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: p53 protein expression
Number of subjects: 93
Study: 21712336

Group type: EXPERIMENTAL
Intervention: Incentivised indicators
Number of subjects: 653500

Group type: COMPARATOR
Intervention: Non-incentivised indicators
Number of subjects: 653500
Study: 19912736

Group type: EXPERIMENTAL
Intervention: Shenyi Capsule combined with gemcitabine plus cisplatin (GP) regimen
Number of subjects: 60
Study: 17127615

Group type: EXPERIMENTAL
Intervention: Enhanced scanning
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional scanning
Number of subjects: 20
Study: 15247911

Group type: EXPERIMENTAL
Intervention: 9-valent pneumococcal conjugate vaccine (PncCV)
Number of subjects: 37107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37107
Study: 11439963

Group type: EXPERIMENTAL
Intervention: Recombinant alpha-galactosidase A
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 9296467

Group type: EXPERIMENTAL
Intervention: Dalteparin (low-molecular-weight heparin)
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Dalteparin (lower dose)
Number of subjects: 1482

Group type: EXPERIMENTAL
Intervention: Dalteparin (twice-daily administration)
Number of subjects: 1482

Group type: COMPARATOR
Intervention: Dalteparin (lower once-daily dose)
Number of subjects: 1482
Study: 8395472

Group type: EXPERIMENTAL
Intervention: 60% high complex/high starch and fibre (HC/HSF‐CHO) and 20% fat (group 1; 11 subjects)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 60% high simple/high natural fibre (HS/HNF‐CHO) and 20% fat (group 2; 7 subjects)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 20% CHO (L‐CHO) and 60% fat (group 3; 7 subjects)
Number of subjects: 25
Study: 3530305

Group type: EXPERIMENTAL
Intervention: Oral lamotrigine (240 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (20 mg)
Number of subjects: 0
Study: 31296073

Group type: EXPERIMENTAL
Intervention: Poractant alpha
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Beractant
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study: 28726590

Group type: EXPERIMENTAL
Intervention: ICE protocol
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Low-/moderate-dose hypertonic saline
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Mild hyperventilation (adjusted partial pressure of carbon dioxide 30-35 mm Hg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Pressors to maintain cerebral perfusion
Number of subjects: 167
Study: 26953566

Group type: EXPERIMENTAL
Intervention: Debriefing-on-demand
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional debriefing
Number of subjects: 8
Study: 24486426

Group type: EXPERIMENTAL
Intervention: Supported Employment (SE) intervention (n=81)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Treatment as usual (C) (n=76)
Number of subjects: 157
Study: 22438027

Group type: EXPERIMENTAL
Intervention: Tacrolimus plus prednisone (n=34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Azathioprine plus prednisone (n=36)
Number of subjects: 70
Study: 19728091

Group type: EXPERIMENTAL
Intervention: Internet-based gender-specific drug prevention program (12 sessions)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 236
Study: 18281663

Group type: EXPERIMENTAL
Intervention: 16-week cardiovascular and strength training exercise intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 101
Study: 15718840

Group type: EXPERIMENTAL
Intervention: Phenotype susceptibility testing (PHENO)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Both groups (PHENO and SOC)
Number of subjects: 238
Study: 14521596

Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Gelofusine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 55
Study: 10492858

Group type: EXPERIMENTAL
Intervention: Twice weekly ECT
Number of subjects: 48

Group type: COMPARATOR
Intervention: Three times weekly ECT
Number of subjects: 48
Study: 8698227

Group type: EXPERIMENTAL
Intervention: Gastric permeability measured by oral or duodenal administration of a triple sugar solution (20 g sucrose, 10 g lactulose, 5 g mannitol in 100 mL water)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Intestinal permeability measured by lactulose/mannitol test
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study: 1894758

Group type: EXPERIMENTAL
Intervention: 150‐mg phenylpropanolamine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75‐mg phenylpropanolamine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75‐mg phenylpropanolamine plus 400‐mg caffeine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6225150

Group type: EXPERIMENTAL
Intervention: Zimelidine (75-300 mg/day)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Amitriptyline (dosage not specified)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 229
Study: 31862664

Group type: EXPERIMENTAL
Intervention: Gait training splint
Number of subjects: 23

Group type: COMPARATOR
Intervention: Baseline walking speed
Number of subjects: 23
Study: 30594339

Group type: EXPERIMENTAL
Intervention: TKA communication checklist
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard of care communication
Number of subjects: 127
Study: 27841155

Group type: EXPERIMENTAL
Intervention: Vilaprisan 1 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vilaprisan 5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vilaprisan 15 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vilaprisan 30 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26925155

Group type: EXPERIMENTAL
Intervention: Early ART
Number of subjects: 755
Study: 25186261

Group type: EXPERIMENTAL
Intervention: tiotropium
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol combination
Number of subjects: 255

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 255
Study: 22247116

Group type: COMPARATOR
Intervention: Surgical castration pre-weaning (CON)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intact bulls (BULL)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bulls castrated by the Callicrate Bander (BAN)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bulls castrated by the Henderson Castrating Tool (HEN)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Bulls castrated surgically utilizing an emasculator (SUR)
Number of subjects: 75
Study: 19164356

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg x day(‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 1,000 microg x day(‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ciclesonide 320 microg x day(‐1)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ciclesonide 640 microg x day(‐1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluticasone propionate 1,000 microg x day(‐1) vs Ciclesonide 320 microg x day(‐1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluticasone propionate 1,000 microg x day(‐1) vs Ciclesonide 640 microg x day(‐1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fluticasone propionate 500 microg x day(‐1) vs Ciclesonide 320 microg x day(‐1)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ciclesonide 640 microg x day(‐1) vs Fluticasone propionate 1,000 microg x day(‐1)
Number of subjects: 32
Study: 16428539

Group type: EXPERIMENTAL
Intervention: SCH 1 mg/kg ideal body weight
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SCH 1 mg/kg lean body weight
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: SCH 1 mg/kg total body weight
Number of subjects: 45
Study: 15571211

Group type: EXPERIMENTAL
Intervention: Febuxostat 10 mg to 120 mg
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 11404656

Group type: EXPERIMENTAL
Intervention: Oxygen (FIO2 = 0.75)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 14
Study: 9146777

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg daily
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 103
Study: 8199904

Group type: EXPERIMENTAL
Intervention: Self-concept assessment using the Tennessee Self-Concept Scale (TSCS)
Number of subjects: 471
Study: 2451929

Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Astemizole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Benzalkonium chloride
Number of subjects: 12

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 12
Study: 30194031

Group type: EXPERIMENTAL
Intervention: ODM-204 (50, 100, 200, 300, and 500mg twice daily)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ODM-204 (200mg and above)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ODM-204
Number of subjects: 23
Study: 30652205

Group type: EXPERIMENTAL
Intervention: Direct provision of an HIV self-test
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Provision of a coupon for facility collection of an HIV self-test
Number of subjects: 960

Group type: COMPARATOR
Intervention: Referral to standard-of-care HIV testing services
Number of subjects: 960
Study: 28181344

Group type: EXPERIMENTAL
Intervention: Expert-facilitated courses that encourage experiential learning
Number of subjects: 20
Study: 26603802

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous haemofiltration (CVVH)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Intermittent haemodialysis (IHD)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Both IHD and CVVH
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: CVVH in patients with sepsis
Number of subjects: 252
Study: 23188892

Group type: EXPERIMENTAL
Intervention: Insulin-based treatment
Number of subjects: 324

Group type: COMPARATOR
Intervention: Oral glucose-lowering agents
Number of subjects: 324
Study: 21602541

Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP) with a polysomnographic cut-off of the apnoea-hypopnoea index (AHI)≥5
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP) with a specific cut-off of AHI>10
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Home respiratory polygraphy (HRP)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Polysomnography
Number of subjects: 366
Study: 18477373

Group type: EXPERIMENTAL
Intervention: Senior Exercise Self‐efficacy Project (SESEP) intervention
Number of subjects: 166

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 166
Study: 15389224

Group type: EXPERIMENTAL
Intervention: Triiodothyronine supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 11669482

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (1450 ppm NaF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluoride-free toothpaste
Number of subjects: 8
Study: 9698952

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.12% with fentanyl 2 micrograms/ml
Number of subjects: 100

Group type: COMPARATOR
Intervention: Bupivacaine 0.24% with fentanyl 4 micrograms/ml
Number of subjects: 100
Study: 8016257

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 11
Study: 2472709

Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiated blood with lymphocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultraviolet irradiated blood without lymphocytes
Number of subjects: 0
Study: 46511

Group type: EXPERIMENTAL
Intervention: Treated group
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study: 30951597

Group type: COMPARATOR
Intervention: 0% CLA
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 1% CLA
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 2% CLA
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: 4% CLA
Number of subjects: 360
Study: 28661759

Group type: EXPERIMENTAL
Intervention: Epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) followed by docetaxel (100 mg/m2; EC-D)
Number of subjects: 2012

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2) and cyclophosphamide (600 mg/m2; DC)
Number of subjects: 2012
Study: 25937436

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin 1000-1200 mg daily for 24 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin 1000-1200 mg daily for 12 weeks
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 12 weeks in patients with cirrhosis
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 24 weeks in patients with cirrhosis
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 12 weeks in patients without cirrhosis
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and ribavirin for 24 weeks in patients without cirrhosis
Number of subjects: 103
Study: 23998146

Group type: EXPERIMENTAL
Intervention: New dentures (Kennedy Class I or II RPDs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: New dentures (Kennedy Class III or IV RPDs)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: New complete dentures
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 72
Study: 21454449

Group type: EXPERIMENTAL
Intervention: Screening group (1494 men)
Number of subjects: 9026

Group type: COMPARATOR
Intervention: Control group (not specified, but implied to be the remaining men)
Number of subjects: 9026

Group type: EXPERIMENTAL
Intervention: Screening group
Number of subjects: 9026

Group type: EXPERIMENTAL
Intervention: Screening group (after adjustment for age)
Number of subjects: 9026
Study: 19803235

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with catgut implantation at acupoints
Number of subjects: 65

Group type: COMPARATOR
Intervention: Electroacupuncture only (control group)
Number of subjects: 65
Study: 16775230

Group type: EXPERIMENTAL
Intervention: subcutaneous interferon beta‐1a at 22 mug, three times weekly
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: subcutaneous interferon beta‐1a
Number of subjects: 24
Study: 15280789

Group type: EXPERIMENTAL
Intervention: HAART plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 28

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 28
Study: 11446955

Group type: EXPERIMENTAL
Intervention: Innovative strategies to optimize results in older patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study: 9252074

Group type: EXPERIMENTAL
Intervention: 3 MU interferon alpha-2b t.i.w. for 21 months
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: 6 MU interferon alpha-2b t.i.w. for 21 months
Number of subjects: 171

Group type: COMPARATOR
Intervention: 3 MU interferon alpha-2b
Number of subjects: 171

Group type: COMPARATOR
Intervention: 6 MU interferon alpha-2b
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Low baseline viremia
Number of subjects: 171

Group type: COMPARATOR
Intervention: Genotype 1b
Number of subjects: 171
Study: 12959273

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (60 mg)
Number of subjects: 0
Study: 3103580

Group type: EXPERIMENTAL
Intervention: Lithium carbonate therapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 29447788

Group type: EXPERIMENTAL
Intervention: Febuxostat for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 30
Study: 27288382

Group type: EXPERIMENTAL
Intervention: Automated identification and notification of clinician of high-risk patients by APPROVE or by invasive MV and checklist of evidence-based practices in ARF (Prevention of Organ Failure Checklist‐PROOFCheck)
Number of subjects: 0
Study: 25483483

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 0
Study: 22545878

Group type: EXPERIMENTAL
Intervention: Postoperative duplex ultrasonography (DUS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Triple-modality early postoperative follow-up protocol (intraoperative angiogram, DUS, and abdominal radiograph)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Triple-modality early postoperative follow-up protocol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Initial postoperative computed tomographic angiography (CTA)
Number of subjects: 100
Study: 19945354

Group type: EXPERIMENTAL
Intervention: Transient sham TENS
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 69

Group type: COMPARATOR
Intervention: Inactive sham
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Higher active TENS amplitudes (> or =17 mAs)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lower active TENS amplitudes (<17 mAs)
Number of subjects: 69
Study: 18306163

Group type: EXPERIMENTAL
Intervention: Combination of Er:YAG laser ablation and ALA methyl ester PDT (method C)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) only (method A)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Er:YAG laser ablation only (method B)
Number of subjects: 286
Study: 15708302

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 14
Study: 11994041

Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg/day for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluconazole 150 mg once weekly for 12 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fluconazole 150 mg once weekly for 24 weeks
Number of subjects: 48
Study: 10460185

Group type: EXPERIMENTAL
Intervention: Active ET plus active US
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Active ET plus dummy US
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dummy ET plus active US
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Dummy ET plus dummy US
Number of subjects: 180

Group type: COMPARATOR
Intervention: No adjuvants
Number of subjects: 180
Study: 8546284

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (propofol and alfentanil)
Number of subjects: 45
Study: 2121846

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg orally every 6 months)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Praziquantel (initial full dose of 40 mg/kg followed by 20 mg/kg every 3 months)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Praziquantel (initial loading dose followed by 20 mg/kg at monthly intervals)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg orally monthly)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg orally every 3 months)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (vitamin B complex tablets at 3-month intervals)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg orally every 6 months for urinary hematobiasis)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Praziquantel (20 mg/kg orally monthly for urinary hematobiasis)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (two vitamin B-complex tablets monthly for urinary hematobiasis)
Number of subjects: 6
Study: 342691

Group type: EXPERIMENTAL
Intervention: Piroxicam (CP 16171)
Number of subjects: 0
Study: 31190359

Group type: EXPERIMENTAL
Intervention: Flaxseed oil (1,000 mg omega-3 fatty acids, twice a day for 12 weeks)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fish oil (1,000 mg omega-3 fatty acids, twice a day for 12 weeks)
Number of subjects: 90
Study: 27988143

Group type: EXPERIMENTAL
Intervention: EUC plus HAP
Number of subjects: 495

Group type: COMPARATOR
Intervention: EUC alone
Number of subjects: 495
Study: 25597870

Group type: EXPERIMENTAL
Intervention: NT-proBNP trajectory post-discharge
Number of subjects: 1351